A brief evidence-based review of two gastrointestinal illnesses: Irritable bowel and leaky gut syndromes

Alternative Therapies in Health and Medicine

Volumn 10, Issue 3, 2004, Pages 22-31+92

  Kiefer, David ^a   Ali Akbarian, Leila ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDIARRHEAL AGENT; ARTICHOKE LEAF EXTRACT; CIMETROPIUM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; HEPAR SL; HERBACEOUS AGENT; ISPAGULA; LOPERAMIDE; MEBEVERINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PADMA LAX; PAROXETINE; PEPPERMINT OIL; PINAVERIUM BROMIDE; PLACEBO; PLANT EXTRACT; PROBIOTIC AGENT; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ALTERNATIVE MEDICINE; ANIMAL MODEL; ARTICHOKE; BEHAVIOR THERAPY; CHILD; CHINESE MEDICINE; COGNITIVE THERAPY; CONTROLLED STUDY; DEPRESSION; DIARRHEA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HERBAL MEDICINE; HUMAN; HYPNOSIS; IRRITABLE COLON; LACTOBACILLUS PLANTARUM; LEAKY GUT SYNDROME; MAJOR CLINICAL STUDY; MENTHA PIPERITA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYNDROME DELINEATION;

CLINICAL TRIALS; COMPLEMENTARY THERAPIES; EVIDENCE-BASED MEDICINE; HUMANS; HYPNOSIS; INTESTINAL ABSORPTION; IRRITABLE BOWEL SYNDROME; MALABSORPTION SYNDROMES; PHYTOTHERAPY; PROBIOTICS; QUALITY OF LIFE; RISK FACTORS;

EID: 2442582570     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Astin JA. Why Patients Use Alternative Medicine: Results of a National Study. JAMA. 1998;279:1548-1553.
2. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trend in Alternative Medicine Use in the United States, 1990-1997: Results of a Follow-up National Survey. JAMA. 1998;280:1569-1575.
3. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(sup 2).II43-II47.
4. Tierney LM, McPhee SJ, Papadakis MA, (eds.). Current Medical Diagnosis and Treatment Adult ambulatory and inpatient management. 41st Edition. New York, New York:Lange Medical Books/McGraw Hill;2002.
5. Camilleri M. Management of the Irritable Bowel Syndrome. Gastroenterology 2001;120(3):652-668.
6. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: Are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol. 2000;95:3176-83.
7. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304:87-90.
8. Talley NJ, Zinsmeister AR and Melton LJ III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 1995;142:76-83.
9. Koloski NA, Talley NJ, Huskic SS, Boyce PM. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2003;17(6):841.
10. Cotran RS, Kumar V and Collins T (eds.). Robbins Pathologic Basis of Disease. 6th Edition. Philadelphia, PA:WB Saunders Company;1999.
11. Camilleri M, Heading RC, Thompson, WG. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16(8):1407-1430.
12. Mayer EA. Emerging disease model for functional gastrointestinal disorders. Am J Med. 1999;107(5,suppl 1):12-19.
13. Kellow JE. Advances in the management of irritable bowel syndrome. J Gastro Hepatology. 2002;17(4):503-510.
14. Neal KR, Hebben J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314:779.
15. García Rodríguez LG and Ruigómez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. 1999;318(7183):565-566.
16. Gwee K-A, Leong Y-L, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400-406.
17. Drossman DA, Creed FH, Olden KW, et al. Psychosocial aspects of the functionalgastrointestinal disorders. Gut. 1999;45(suppl 2):II25-II30.
18. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut. 1997;41(3):394-398.
19. Mayer EM, Naliboff BD, Chang L, Coutinho SV. Stress and the Gastrointestinal Tract V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2001;280(4):G519-G524.
20. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel syndrome. BMJ. 1978;ii:653-554.
21. Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: Guidelines for the diagnosis. Gastroenterol Int. 1990;3:92-95.
22. Mearin, M, Roset M, Badia X, et al. Splitting Irritable Bowel Syndrome: From Original Rome to Rome II Criteria. Am J Gastroenterol. 2004;99(1):122-130.
23. American Gastroenterological Association Medical Position Statement: Irritable Bowel Syndrome. Gastroenterology. 1997;112:2118-2119.
24. Drossman DA, Whitehead WE, Camilleri M. Irritable Bowel Syndrome: A Technical Review for Practice Guideline Development. Gastroenterology. 1997;112:2120-2137.
25. Kellow JE. Advances in the management of irritable bowel syndrome. J Gastro Hepatology. 2002;17(4):503.
26. Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE. Psychosocial aspects of the functional gastrointestinal disorders. Gut. 1999;45(Suppl 2):II25-II30.
27. Somers SC, Lembo A. Irritable bowel syndrome: evaluation and treatment. Gastroenterology Clinics. 2003;32(2):505-529.
28. Camilleri M, Heading RC, Thompson WG. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:1407-1430
29. University of Arizona College of Medicine Program in Integrative Medicine. www.integrativemedicine.arizona.edu. Accessed: 3/13/04.
30. Lutz RB. Irritable Bowel Syndrome. In: Rakel D (ed.). Integrative Medicine. Philadelphia, PA:Saunders;2003.
31. Klein KB. Controlled Treatment Trials in the Irritable Bowel Syndrome. Gastroenterology. 1988;95:232-241.
32. Jaiwala J, Imperiale TF, Kroenke. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136-147.
33. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomized controlled trials. Gut. 2001;48:272-282.
34. Thompson WG. Review article: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:1395-1406.
35. Talley NJ. Pharmacologic Therapy for irritable Bowel Syndrome. Am J Gastroenterol. 2003;98)4):750-758.
36. Jackson JL, O'Malley PG, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressants: a meta-analysis. Am J Med. 2000;108(1):65-72.
37. Poynard T, Regimgeau C, Benhaumou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15:355-361.
38. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B. The Cost-Effectiveness of Psychotherapy and Paroxetine for Severe Irritable Bowel Syndrome. Gastroenterology. 2003;124(2):303-317.
39. DeLor J. The Irritable Bowel Syndrome. Am J Gastroenterology. 1967;47:427-34.
40. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological Treatments for Irritable Bowel Syndrome: A Critique of Controlled Treatment Trials. Am J Gastroenterology. 1996;91(2):277-286.
41. Keefer L, Blanchard EB. The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. Behaviour Res Ther. 2001;39(7):801-11.
42. Keefer L, Blanchard EB. A one year follow-up of relaxation response meditation as a treatment for irritable bowel syndrome. Behaviour Res Ther. 2002;40(5):541-6.
43. Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol. 2003;98(10):2209-2218.
44. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome. Lancet. 1984;2:1232-1234.
45. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol. 2002;97(4):954-61.
46. Palsson OS, Turner MJ, Johnson DA, Burnelt CK, Whitehead WE. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci. 2002;47(11):2605-14.
47. Forbes A, MacAuley S, Chiotakakou-Faliakou E. Hypnotherapy and therapeutic audio-tape: effective in previously unsuccessfully treated irritable bowel syndrome. Int J Colorectal Dis. 2000;15(5-6):328-34.
48. Galovski TE, Blanchard EB. The Treatment of Irritable Bowel Syndrome with Hypnotherapy. Applied Psychophysiol Biofeedback. 1998;23(4):219-32.
49. Whorwell PJ. Hypnotherapy in the irritable bowel syndrome. Stress Med. 1987;3:5-7.
50. Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut. 2003;52(11):1623-9.
51. Bensoussan A, Talley, NJ, Hing M, Menzies R. Treatment of Irritable Bowel Syndrome With Chinese Herbal Medicine. JAMA. 1998;280:1585-1589.
52. Sallon S, Ben-Arye E, Davidson R, et al. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion. 2002;65(3):161-71.
53. Kraft, K. Artichoke leaf extract - recent findings reflecting effects on lipid metabolism, liver and gastrointestinal tracts. Phytomedicine. 1997;4:369-378.
54. Walker AF, Middleton RW, Petrowicz O. Artichoke Leaf Extract Reduces Symptoms of Irritable Bowel Syndrome in a Post-marketing Surveillance Study. Phytotherapy Research. 2001;15:58-61.
55. Rees WD. Treating irritable bowel syndrome with peppermint oil. BMJ. 1979;2:835-836.
56. Leicester RJ and Hunt RH. Peppermint oil to reduce colonic spasm during endoscopy. Lancet. 1982;989.
57. Mills S, Bone K. Principles and Practice of Phytotherapy. Edinburgh, England:Churchill Livingstone:2000.
58. Evans BK, Heatley RV, James CK, Luscombe DK. Further studies on the correlation between biological activity and solubility of some carminatives. J PHARM Pharmacol.1975:27(suppl):66.
59. Hills JM, Aaronson PI. The mechanism of action of peppermint on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991;101:55-65.
60. Dew MI, Evans BK, and Rhodes J. Peppermint oil for the irritable bowel syndrome: a multicenter trial. Br J Clin Pract. 1984;38:394-8.
61. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001:138(1);125-128.
62. Sagduyu K. Peppermint Oil for Irritable Bowel Syndrome. Psychosomatics. 2002;43(6):508-509.
63. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroent. 1998;93(7):1131-1135.
64. Nash P, Gould SR, Barnardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. Br J Clin Pract. 1986;40:292-3.
65. Nobaek S, Johansson M-L, Molin G, Ahrne S et al. Alteration of intestinal microflora is associated with recuction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroent. 2000;95(5):1231-1238.
66. Fooks LF and Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr. 2002;88(suppl 1):S39-S49.
67. Madden JAJ, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr. 2002;88 (suppl 1):S67-S72.
68. Guarne F, Schaafsma GJ. Probiotics. Int J Food Microbiol. 1998;39(3):237-238.
69. Hollander D. The intestinal permeability barrier: a hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol. 1992;27:721-726.
70. Sierpina VA, Carter R. Alternative and Integrative Treatment of Fibromyalgia and Chronic Fatigue Syndrome. Clin Fam Pract. 2002;4(4):853.
71. Cantor IS, Rosenzwieg S. Anthroposophic perspective in primary care. Prim Care. 1997;24(4):867-887
72. Ma TY. Intestinal epithelial barrier dysfunction in Crohn's disease. Proceedings of the Society for Experimental Biology & Medicine. 1997;214(4):318-27.
73. Pizzorno J. Textbook of Natural Medicine. Second Edition. Churchill Livinstone:;1999.
74. Hollander D. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg? American Journal of Gastroenterology. 2002;97(8):1867-8.
75. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Putgeerts P. Anti-Tumor Necrosis Factor Treatment Restores the Gut Barrier in Crohn's Disease. Am J Gastroenterol. 2002;97:2000-2004.
76. Keshavarzian A, Holmes EW, Patel N, Iber F, Fields JZ and Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol. 1999;94:200-207.
77. Gardiner KR, Halliday MI, Barchy GR. Significance of systemic endotoxemia in inflammatory bowel disease. Gut. 1995;36:897-901.
78. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy. Gastroenterology 1997;112:1000-1016.
79. Bjamason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anit-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986;27:1292-1297.
80. Jenkins AP, Trew DR, Crump BJ, Nukajam WS, Foley JA, Menzies IS, Creamer B. Do non-steroidal anti-inflammatory drugs increase colonic permeability? Gut. 1991;32:66-69.
81. Bjamason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut. 1991;2:275-277.
82. Campieri M and Gionchetti P. Probiotics in inflammatory bowel disease: new insights to pathogenesis or a possible therapeutic alternative? Gastroenterology. 1999;116: 1246-1260.
83. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, Jeppsson B. The effects of lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 1996;111:334-344.
84. Fink MP. Leaky gut hypothesis: a historical perspective. Crit Care Med. 1990;18(5):579-80.
85. Van Deventer SJH, ten Cate JW, Typat GNJ. Intestinal endotoxemia: Clinical significance. Gastroenterology. 1988;94:825-831.
86. Deitch EA, Morrison J, Bergf R, et al. Effect of hemorrhagic shock on bacterial translocation, intestinal morphology, and intestinal permeability in conventional and antibiotic-decontaminated rats. Crit Care Med. 1990;18:529-536.
87. Madara JL. Pathobiology of the intestinal epithelial barrier. Am J Pathol. 1990;137:1273-1281.
88. Jackson PG, Lessof MH, Baker RWR, Ferrett I, MacDonald DM. Intestinal permeability in patients with eczema and food allergy. Lancet. 1981;1:1285-1286.
89. Strobel S, Brydon WG and Ferguson A. Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum. Gut. 1984;25:1241-1246.
90. Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: An Overview. Gastroenterology. 1995;108:1566-1581.
91. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal Permeability Changes in Response to Acetylsalicylic Acid in Relatives of Patients With Crohn's Disease. Gastroenterology. 1996;110:1395-1403.
92. Pironi L, Miglioli M, Ruggeri E, Callasta MA, Ornigotti L, Valpiani D, Barbara L. Effect of Non-steroidal Anti-inflammatory Drugs (NSAID) on Intestinal Permeability in First-Degree Relatives of Patients With Crohn's Disease. Gastroenterology. 1992;102:A679
93. Lee CC, Marill KA, Carter WA, Crupi RS. A current concept of trauma-induced multi-organ failure. Ann Emerg Med. 2001;38(2):170-176.
94. Pastores SM, Katz DP, Kvetan V. Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Am J Gastroenterol. 1996;91:1697-1710.
95. Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ and Bjarnason I (1998) Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998;43:506-511.
96. Inca RD, Leo VD, Martines OM, Mancin O, Lecis PE, Biancon G, Sturniolo GC, Naccaratto R. Permeability of sugars can be helpful in predicting disease activity in Crohn's disease. Gastroenterology. 1992;102:A616.
97. Ito K, Hiwatashi N, Kinouchi Y, Yamazaki H, Toyota T. Improvement of abnormal intestinal permeability in active Crohn's disease by an elemental diet. Gastroenterology. 1992;102:A641.
98. Sugino K, Dohi K, Yamada K, et al. The role of lipid peroxidation in endotoxin-induced hepatic damage and the protective effects of antioxidants. Surgery. 1987;101:746-752.